Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies

NCT00504972 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia

Interventions

DRUG: hLL1

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]